Skip to main content

Advertisement

Table 1 Demographics and patient characteristics (safety set)

From: A randomised, double-blind clinical phase II trial of the efficacy, safety, tolerability and pharmacokinetics of a single dose combination treatment with artefenomel and piperaquine in adults and children with uncomplicated Plasmodium falciparum malaria

All patients   800:640 (N = 143) 800:960 (N = 148) 800:1440 (N = 146) Total (N = 437)
Africa Number (n) 116 121 118 355
Age (years) (derived) Median 3.30 3.20 2.90 3.10
(Min., max.) (0.5, 54.3) (0.8, 44.6) (0.5, 37.7) (0.5, 54.3)
  > 15.0 years n (%) 15 (12.9) 16 (13.2) 14 (11.9) 45 (12.7)
  > 5.0 to ≤ 15.0 years n (%) 7 (6.0) 7 (5.8) 8 (6.8) 22 (6.2)
  > 2.0 to ≤ 5.0 years n (%) 69 (59.5) 72 (59.5) 70 (59.3) 211 (59.4)
  ≥ 0.5 to ≤ 2.0 years n (%) 25 (21.6) 26 (21.5) 26 (22.0) 77 (21.7)
 Male n (%) 56 (48.3) 63 (52.1) 70 (59.3) 189 (53.2)
Vietnam n 27 27 28 82
Age (years) (derived) Median 27.30 27.30 28.60 27.45
(Min., max.) (12.5, 48.5) (9.7, 60.0) (13.3, 57.6) (9.7, 60.0)
  > 15.0 years n (%) 26 (96.3) 26 (96.3) 27 (96.4) 79 (96.3)
  > 5.0 to ≤ 15.0 years n (%) 1 (3.7) 1 (3.7) 1 (3.6) 3 (3.7)
  > 2.0 to ≤ 5.0 years n (%) 0 0 0 0
  ≥ 0.5 to ≤ 2.0 years n (%) 0 0 0 0
 Male n (%) 27 (100.0) 22 (81.5) 28 (100.0) 77 (93.9)
  1. n number of patients in each category/%)